Corporate Presentation

T1DM We aim to shift the paradigm in the management of T1D by using dasiglucagon Severe hypoglycemia Z ZEGALOGUE (dasiglucagon) injection 06mg/06 ml autoinjector Exercise-induced hypoglycemia* SAMPLE ZEAL& ZEALAND PHARMA Automated glucose management* ---- ZEGALOGUE (dasiglucagon) injection 0.6 mg/06 m TIS123A Severe hypoglycemia associated with significant morbidity and mortality1 Approved in the U.S. for + pediatric and adult patients with diabetes aged >6 years Partnership with Novo Nordisk for commercialization and further development MAA submitted in June 2023 ॐ Mini-dose pen (investigational device) Physical activity is recommended for individuals living with diabetes² Current recommendations for Einsulin/blood sugar management during exercise are complex² Despite innovation people with diabetes remain at significant risk of EIH Phase 2 IITs completed iLetⓇ bihormonal bionic pancreas (investigational device) Only 20% of people with T1 diabetes achieve glycemic goals³ 90% of subjects on Phase 2 study of BHBP achieved ADA treatment goals4 A staged, phase 3 program to evaluate ~700 adults and children to begin in 2023 * investigational compounds whose safety and efficacy have not been evaluated or approved by the FDA or any other regulatory authority Ready for Phase 3 1 ADA Standards of care. Diabetes Care 2021 Jan; 44 (Supplement 1): S1-S2; 2 Colberg SR et al. Diabetes Care. 2016;39:2065-2079;; 3 Pettus et al., Diabetes Care (2019) 42(12):2220-2227; 4 S. Russell et al. 2020. Conference. Diabetes Technology & Therapeutics. Page A-53; MAA = Marketing Authorisation Application 46

View entire presentation